Welcome to our dedicated page for Zepp Health Corporation SEC filings (Ticker: ZEPP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Zepp Health Corporation (NYSE: ZEPP) regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a foreign private issuer, Zepp Health submits annual reports on Form 20-F and current reports on Form 6-K, alongside other required documents related to its American depositary shares, each representing sixteen Class A ordinary shares.
Through these SEC filings, investors can review information about Zepp Health’s smart wearable and health technology business, which includes the Amazfit, Zepp Clarity and Zepp Aura brands. Filings such as the Form 20-F typically contain details on the company’s operations, risk factors, industry classification in electromedical and electrotherapeutic apparatus manufacturing, and corporate history, including its origin as Huami Corp. and subsequent name change to Zepp Health Corporation.
Form 6-K current reports often furnish press releases and other updates, such as announcements of unaudited quarterly financial results or other material information. For example, recent 6-K filings reference press releases regarding financial performance and confirm Zepp Health Corporation as the registrant with its principal office in Gorinchem, the Netherlands.
On this page, users can quickly locate annual reports (Form 20-F), current reports (Form 6-K) and other relevant submissions as they are made available through EDGAR. Stock Titan enhances these documents with AI-powered summaries that explain key points in accessible language, helping readers interpret complex sections on operating metrics, product portfolio, capital structure and strategic initiatives without reading every line of the original filing.
For those researching ZEPP regulatory history, this filings archive offers a structured view of how Zepp Health reports its business evolution, financial condition and risk profile over time, complementing the company’s news releases and other public communications.
Zepp Health Corp director Xie Bing (Brian) has filed an initial statement of beneficial ownership on Form 3. The filing establishes his status as a director and does not report any insider buy, sell, or other share transactions.
Zepp Health Corp director Lai Jimmy Y. filed an initial statement of beneficial ownership on Form 3. This filing establishes his status as a reporting insider under securities rules and does not report any stock purchases, sales, or other transactions in Zepp Health shares.
Zepp Health Corp Chief Technology Officer Meihui Fan has filed an initial statement of beneficial ownership, detailing existing equity and option interests rather than new trades. The filing lists several option awards over Class A ordinary shares with a conversion or exercise price of US$0.0000, covering 160,000, 200,000, 80,000 and 80,000 underlying Class A shares with expirations between 2031 and 2034. It also reports indirect holdings of 432,000 Class A ordinary shares and 3,450,746 Class B ordinary shares held by Fandler Holding Limited, which is ultimately owned by a trust for Mr. Fan and his family members. In addition, Mr. Fan directly holds 10,000 American depositary shares, with each ADS representing 16 Class A ordinary shares.
Zepp Health Corp Chief Financial Officer Deng Cheng filed an initial ownership report on Form 3, showing direct holdings of 101,500 American depositary shares (ADSs). Each ADS represents 16 Class A ordinary shares, meaning this filing simply discloses his existing equity stake rather than reporting a new stock transaction.
Zepp Health Corp executive Wang Hui, VP of Corporate Strategy, has filed an initial ownership report showing a substantial equity stake. He directly holds 1,495,500 Class A ordinary shares and several option awards over additional Class A shares, each with a $0.0000 exercise price and expirations ranging from 2030 to 2034. These entries reflect existing holdings rather than new market purchases or sales.
Zepp Health Corp director and Chief Operating Officer Mike Yan Yeung filed an initial ownership report showing his holdings in the company. He reported Class A ordinary shares and separate holdings of American depositary shares (ADSs). Each ADS represents 16 Class A ordinary shares, according to the disclosure.
Zepp Health Corp insider Yu Pengtao, the company’s Chief Industrial Designer, filed an initial ownership report showing holdings of 108,491 American depositary shares. Each ADS represents 16 Class A ordinary shares, so this filing mainly establishes his existing equity stake rather than reporting a new trade.
Zepp Health Corp director and CEO Huang Wang filed an initial ownership report showing substantial holdings in the company. He indirectly owns 65,836,680 Class B ordinary shares through HHtech Holdings Limited, which is ultimately owned by a trust established for the benefit of Mr. Wang and his family members.
He also indirectly holds 237,500 American depositary shares (ADSs) through HHtech Holdings Limited and directly holds 60,076 ADSs. Each ADS represents 16 Class A ordinary shares, giving him significant economic exposure and voting influence over Zepp Health.
Zepp Health Corporation reported rapid growth for the fourth quarter and full year 2025, pairing strong sales momentum with narrower losses. Fourth quarter 2025 revenue reached US$85.2 million, up 43.0% year over year and 12.4% sequentially, while gross margin climbed to a record 40.4% from 36.8% a year earlier, helped by a richer Amazfit product mix and sustained pricing.
Despite higher selling, marketing and general administrative costs, including US$5.2 million in special provisions and brand/IP expenses, profitability improved. Adjusted operating loss in the quarter shrank to US$2.7 million from US$7.4 million, and net loss fell to US$11.0 million from US$36.9 million. For full year 2025, revenue rose 41.8% to US$258.9 million, with net loss reduced to US$40.1 million from US$75.7 million and adjusted net loss down to US$31.5 million from US$56.7 million. Cash and restricted cash totaled US$112.9 million at year-end, inventory was US$72.8 million, cumulative debt retired since 2023 reached US$58.2 million, and the company has repurchased US$16.2 million (about 2.2 million ADSs) under a buyback program extended through November 2026. Management guides first quarter 2026 revenue of US$50.0–55.0 million, implying 30% to 43% year-over-year growth.
Zepp Health Corp director Lam Sai Wai Alain filed an initial Form 3, which is a statement of beneficial ownership of the company’s securities. The filing does not report any buy or sell transactions and serves to formally register his insider ownership status with regulators.